Sign in
4

Changes in Ownership

RECURSION PHARMACEUTICALS, INC. Filed Acc 0001628280-25-004086

Chief R&D Commercial Officer gave up 2,753 shares (to pay taxes)

  • Chief R&D Commercial Officer acquired 218,162 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Khan Najat · Chief R&D Commercial Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2025-02-03 Grant or award : show line 1 in the form +210,113 707,085 D
2025-02-03 Grant or award : show line 2 in the form +8,049 715,134 D
2025-02-03 Shares withheld for taxes : show line 3 in the form −2,753 $7.25 $19,959 712,381 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2025-02-03 Grant or award : show line 4 in the form Stock Option (Right to Buy) +420,226 420,226 D
Loading xslF345X05/wk-form4_1738792220.xml…